Abstract: The present disclosure provides an antibody for inducing immune tolerance, an induced lymphocyte, and a cell therapy agent therapeutic method using the induced lymphocyte. Specifically, the present disclosure provides an antibody that inhibits the interaction between CD80 and/or CD86 expressed on the surface of a certain cell and CD28 expressed on the surface of another cell, and substantially does not induce immune activation-induced cytokines. In a specific embodiment, the Fc portion of the antibody substantially does not produce the immune activation-induced cytokines.

Abstract: The present disclosure provides a pharmaceutical composition for antigen-specific immune tolerance or immune suppression. The present disclosure provides a pharmaceutical composition comprising a CD4-positive anergy T cell and a CD8-positive anergy T cell. In some embodiments, the anergy T cell is induced by an antibody capable of inhibiting the interaction between CD80 and/or CD86 and CD28. In a specific embodiment, the pharmaceutical composition may additionally comprise a regulatory T cell (e.g., a FOXP3-positive CD4-positive CD25-positive T cell).

Abstract: The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering to an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80/CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

Abstract: The present application relates to generation of regulatory T cells. The present application also relates to uses of the regulatory T cells in treating subjects undergoing organ transplantation. The present application also relates to uses of the regulatory T cells in treating subjects undergoing tissue grafts. Regulatory T cells may be administered to a subject along with one or more antibodies.

Abstract: A combined-blade open flow path device is a fluid flow path device where flow paths are adjacent to each other. The combined-blade open flow path device comprises a substrate configured to constitute a bottom portion of the flow paths; and blades erected on a surface of the substrate, the blades being configured to constitute side walls of the flow paths, wherein the blades are erected in groups, each of the groups extending from an upstream side to a downstream side in a flow direction of a fluid with a space between each of the blades in the flow direction of the fluid in each of the groups for making conduction of the fluid between the adjacent flow paths possible, and wherein one end of one of the flow paths is configured to be in contact with the fluid and is configured to make a flow of the fluid possible.

Abstract: The present invention addresses the problem of providing an antibody titer-increasing agent, such as an adjuvant, capable of sustaining an effect achieved by, for example, vaccination, which is an antibody titer-increasing agent such as an adjuvant that is safe, convenient and economical and can be easily taken irrespective of age, and a method for manufacturing the same. A method for increasing an antibody titer and a method for enhancing the effect of a vaccine, each method comprising using Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof; and an antibody titer-increasing agent such as an adjuvant that comprises Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof.

Abstract: A combined-blade-type open flow path device being a fluid flow path device where a plurality of flow paths are adjacent to each other, the combined-blade-type open flow path device comprising: a substrate configured to constitute a bottom portion of the flow paths; and a plurality of blades erected on a surface of the substrate, the plurality of blades configured to constitute side walls of the flow paths, wherein the plurality of blades are erected in a plurality of numbers at a space in a direction from an upstream side to a downstream side of a flow of the fluid, and conduction of the fluid between the flow paths adjacent at the space is made possible, and wherein the flow of the fluid is made possible by one end of the flow path being in contact with the fluid.

Abstract: The present application relates to generation of regulatory T cells, particularly those generated in the presence of anti-CD80 and anti-CD86 antibodies. The present application also relates to uses of the regulatory T cells in treating subjects undergoing organ transplantation. The present application also relates to uses of the regulatory T cells in treating subjects undergoing tissue grafts. Regulatory T cells may be administered to a subject along with one or more antibodies.

Abstract: The invention provides monoclonal antibodies, which specifically react with a Fas ligand, or active fragments thereof, a production process of the monoclonal antibodies, which specifically react with a Fas ligand, hybridomas separately producing a monoclonal antibody, which specifically reacts with a Fas ligand present on a cell surface, a method of detecting a Fas ligand in a solution, and a kit for use in detecting a Fas ligand, comprising plurality of monoclonal antibodies against Fas ligand in combination.

Abstract: Novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are provided, and a site on Fas ligand which is important to inhibit apoptosis induced by the Fas-Fas ligand interaction against Fas-expressing cells is demonstrated. The novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are prepared from hybridomas which produce monoclonal antibodies specifically reactive to Fas ligand, via recombinant DNA techniques. The humanized immunoglobulins can inhibit the physiological reactions between Fas ligand and Fas such as apoptosis. Further, identification of the site which is on Fas ligand and responsible for apoptosis induction allows creation of recombinant proteins or peptides which are specifically reactive to the amino acids within the site so as to inhibit apoptosis, and to find new therapeutic or diagnostic agents.

Abstract: This invention relates to a TRAF family molecule, a polynucleotide encoding the molecules, an antibody against the molecules, and an antisense polynucleotide of the molecule. Employing an oligo-DNA primer capable of amplifying the most highly conserved region of a known TRAF family molecule, PCR was performed with the aid of cDNA derived from various cell strains and tissues as a template. Thus, the base sequence of the gene of an unknown TRAF family molecule and the amino acid sequence of the TRAF family molecule encoded by the gene were elucidated. An antibody against the molecule was also prepared. By utilizing the TRAF family molecules, genes thereof, and antibodies against the molecules, there are provided methods for elucidating the functions of the proteins and methods for elucidating the signal transduction system of the TNF-R family involving the molecules, as well as probes for research and diagosis, which suggest applications in therapeutic agents.

Abstract: Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha. chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha. chain. The composition is clinically useful for blocking allergic responses.

Abstract: The invention provides therapeutic agents for hepatitis, comprising an antibody against a human Fas ligand, or an active fragment thereof as an active ingredient. The therapeutic agents for hepatitis according to the invention are particularly effective for the treatment of hepatitis caused by the death of hepatocytes due to apoptosis among many kinds of hepatitis.

Abstract: Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha.-chain. The composition is clinically useful for blocking allergic responses. An animal model for use in the screening of prophylactic and therapeutic compositions for IgE-related diseases is also disclosed.

Abstract: A drug for the treatment of rheumatoid arthritis, which comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2. Preferable drug for the treatment of rheumatoid arthritis comprises as an active ingredient a monoclonal antibody which recognizes specifically extracellular region of human VLA-2, .alpha. chain. The above drug for the treatment of rheumatoid arthritis can suppress swelling due to arthritis in rheumatoid arthritis with low toxicity and hence is useful for the treatment of rheumatoid arthritis.

Abstract: A monoclonal antibody specifically reactive to hamster immunoglobulins, a hybridoma producing said monoclonal antibody, and an immunoassay utilizing said monoclonal antibody are provided. The monoclonal antibody is useful in an immunoassay as a secondary antibody to a hamster-derived primary antibody or antiserum raised against various antigens.